Bausch Health Companies Inc.
$5.91
▼
-4.12%
2026-04-21 05:39:00
www.bauschhealth.com
NYQ: BHC
Explore Bausch Health Companies Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.02 B
Current Price
$5.91
52W High / Low
$11.97 / $6.06
Stock P/E
14.05
Book Value
$-1.5
Dividend Yield
—
ROCE
9.85%
ROE
4.36%
Face Value
—
EPS
$0.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
20,300
Beta
0.4
Debt / Equity
5,591.25
Current Ratio
1.47
Quick Ratio
1.08
Forward P/E
1.39
Price / Sales
0.2
Enterprise Value
$22.78 B
EV / EBITDA
6.7
EV / Revenue
2.22
Rating
None
Target Price
$7.71
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Esperion Therapeutics, Inc. | $2.02 | — | $510.15 M | — | 36.51% | 6.57% | $4.17 / $0.69 | $-1.23 |
| 2. | Amneal Pharmaceuticals, Inc. | $13.26 | 58.7 | $4.23 B | — | 14.23% | -80.04% | $15.42 / $7.01 | $-0.23 |
| 3. | Evolus, Inc. | $5.08 | — | $330.5 M | — | -24.97% | 587.36% | $12.28 / $3.86 | $-0.35 |
| 4. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
| 5. | Dr. Reddy's Laboratories Limited | $12.97 | 17.86 | $11.1 B | 0.65% | 19.86% | 16.1% | $1,379.7 / $1,129 | $4.78 |
| 6. | SCYNEXIS, Inc. | $1.07 | — | $47.85 M | — | -30.16% | -16.48% | $1.31 / $0.56 | $1.13 |
| 7. | Aquestive Therapeutics, Inc. | $4.24 | — | $527.23 M | — | -62.98% | 178.61% | $7.55 / $2.12 | $-0.28 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 2.8 B | 2.68 B | 2.53 B | 2.26 B | 2.56 B |
| Operating Profit | 829 M | 636 M | 457 M | 292 M | 608 M |
| Net Profit | -112 M | 179 M | 148 M | -58 M | 93 M |
| EPS in Rs | -0.3 | 0.48 | 0.4 | -0.16 | 0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 10.27 B | 9.62 B | 8.76 B | 8.12 B |
| Operating Profit | 2.19 B | 1.85 B | 1.6 B | 1.39 B |
| Net Profit | 157 M | -46 M | -592 M | -225 M |
| EPS in Rs | 0.42 | -0.12 | -1.59 | -0.6 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 26.37 B | 26.52 B | 27.35 B | 25.69 B |
| Total Liabilities | 25.99 B | 26.84 B | 27.43 B | 25.43 B |
| Equity | -554 M | -1.28 B | -1.02 B | -692 M |
| Current Assets | 6.16 B | 5.77 B | 5.6 B | 4.25 B |
| Current Liabilities | 4.18 B | 6.75 B | 4.3 B | 3.94 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.4 B | 1.6 B | 1.03 B | -728 M |
| Investing CF | -595 M | -454 M | -2.15 B | -303 M |
| Financing CF | -742 M | -868 M | 1.48 B | -474 M |
| Free CF | 993 M | 1.26 B | 760 M | -996 M |
| Capex | -407 M | -340 M | -272 M | -268 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 9.91% | 7.79% | — | — |
| Earnings Growth % | 92.23% | -163.11% | — | — |
| Profit Margin % | -0.48% | -6.76% | -2.77% | — |
| Operating Margin % | 19.26% | 18.27% | 17.12% | — |
| Gross Margin % | 71.1% | 70.78% | 70.9% | — |
| EBITDA Margin % | 29.32% | 25.15% | 33.59% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.